I get why they are recognising the revenue. As the Hologic deal...

I get why they are recognising the revenue. As the Hologic deal is a 12 month play and Hologic have been paying for ongoing services previously per quarter (not their previous revenues have been anywhere from $2M-$4M per month prior years), they are not going to obtain ongoing revenues from Hologic for this deal. So they need to recognise the revenue over each quarter to reaffirm their typical $3Million per month revenues.

I don't agree with it. Its a fluffed way to appease new investors who don't conduct complete due diligence in the company and just scan the reports for those kinds of figures.

Fact is, the prior quarter would have shown revenue of $10Million+USD from that deal and then this month would have shown $1.9Million. Most new investors would probably shy on the edge of caution when seeing that.

They need to:

- Clarify any and all deal they have on the services side and make it abundantly clear on what they all mean. Eg. BINX and the new STI thing. Instead of quoting reimbursement rates, quote facts on figures. No one outside of that industry would really understand what the reimbursment means on a revenue point of view and they need to clear all that up. I get they cant say "FFN is this and we will earn this" but for their own products they can provide a clearer understanding of where things are at.

- Reduce the burn. the $2.6Million seems quite high. What's that for? Pascal units are capped at $300,000 revenue for AT1 so the cost of producing Febridx cant be that dramatic. That $300K is also from 2 buyers, not just Lumos. If they are burning funds from development of Leelu readers etc, then outline sales / leasing revenue from these units granularly. We know that each unit costs around $5KUSD.

- Talk to the AUS region and expand awareness of deals and use of the product here. Your investors are Australian. We understand the US is a bigger play long term, but if the product is available here, advertised here etc, you gain further shareholder interest.